Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment
CONCLUSIONS: According to our results, everolimus accelerates tumor mass reduction, but not amount of mass regression in the long term. Everolimus may be considered for treatment of rhabdomyomas which cause hemodynamic compromise or life-threatening arrhythmias before surgical intervention.PMID:37395967 | DOI:10.24953/turkjped.2022.922 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - July 3, 2023 Category: Pediatrics Authors: Sayg ın Yıldırım Ebru Aypar Bur ça Aydın Canan Aky üz Hayrettin Hakan Aykan İlker Ertuğrul Tevfik Karag öz Dursun Alehan Source Type: research
Management of primary cardiac leiomyosarcoma
CONCLUSION: The nonspecific symptoms presented in the reported case demonstrate that the cardiac tumour can mimic other cardiac disorders, such as coronary artery disease or pericarditis, rarely representing the first manifestation of a previously unknown malignancy.PMID:37396103 | PMC:PMC10310325 | DOI:10.3332/ecancer.2023.1562 (Source: Ecancermedicalscience)
Source: Ecancermedicalscience - July 3, 2023 Category: Cancer & Oncology Authors: Lucrecia Aline Cabral Formigosa Luciana Ferreira Dos Santos Jaqueline Dantas Neres Martins Bianca Silva de Brito Hemilly Vasconcelos de Miranda Silva Ricardo Luiz Saldanha da Silva Josinete da Concei ção Barros do Carmo Samara Machado Castilho Source Type: research
Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment
CONCLUSIONS: According to our results, everolimus accelerates tumor mass reduction, but not amount of mass regression in the long term. Everolimus may be considered for treatment of rhabdomyomas which cause hemodynamic compromise or life-threatening arrhythmias before surgical intervention.PMID:37395967 | DOI:10.24953/turkjped.2022.922 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - July 3, 2023 Category: Pediatrics Authors: Sayg ın Yıldırım Ebru Aypar Bur ça Aydın Canan Aky üz Hayrettin Hakan Aykan İlker Ertuğrul Tevfik Karag öz Dursun Alehan Source Type: research
Management of primary cardiac leiomyosarcoma
CONCLUSION: The nonspecific symptoms presented in the reported case demonstrate that the cardiac tumour can mimic other cardiac disorders, such as coronary artery disease or pericarditis, rarely representing the first manifestation of a previously unknown malignancy.PMID:37396103 | PMC:PMC10310325 | DOI:10.3332/ecancer.2023.1562 (Source: Ecancermedicalscience)
Source: Ecancermedicalscience - July 3, 2023 Category: Cancer & Oncology Authors: Lucrecia Aline Cabral Formigosa Luciana Ferreira Dos Santos Jaqueline Dantas Neres Martins Bianca Silva de Brito Hemilly Vasconcelos de Miranda Silva Ricardo Luiz Saldanha da Silva Josinete da Concei ção Barros do Carmo Samara Machado Castilho Source Type: research
Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment
CONCLUSIONS: According to our results, everolimus accelerates tumor mass reduction, but not amount of mass regression in the long term. Everolimus may be considered for treatment of rhabdomyomas which cause hemodynamic compromise or life-threatening arrhythmias before surgical intervention.PMID:37395967 | DOI:10.24953/turkjped.2022.922 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - July 3, 2023 Category: Pediatrics Authors: Sayg ın Yıldırım Ebru Aypar Bur ça Aydın Canan Aky üz Hayrettin Hakan Aykan İlker Ertuğrul Tevfik Karag öz Dursun Alehan Source Type: research
Management of primary cardiac leiomyosarcoma
CONCLUSION: The nonspecific symptoms presented in the reported case demonstrate that the cardiac tumour can mimic other cardiac disorders, such as coronary artery disease or pericarditis, rarely representing the first manifestation of a previously unknown malignancy.PMID:37396103 | PMC:PMC10310325 | DOI:10.3332/ecancer.2023.1562 (Source: Ecancermedicalscience)
Source: Ecancermedicalscience - July 3, 2023 Category: Cancer & Oncology Authors: Lucrecia Aline Cabral Formigosa Luciana Ferreira Dos Santos Jaqueline Dantas Neres Martins Bianca Silva de Brito Hemilly Vasconcelos de Miranda Silva Ricardo Luiz Saldanha da Silva Josinete da Concei ção Barros do Carmo Samara Machado Castilho Source Type: research
Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment
CONCLUSIONS: According to our results, everolimus accelerates tumor mass reduction, but not amount of mass regression in the long term. Everolimus may be considered for treatment of rhabdomyomas which cause hemodynamic compromise or life-threatening arrhythmias before surgical intervention.PMID:37395967 | DOI:10.24953/turkjped.2022.922 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - July 3, 2023 Category: Pediatrics Authors: Sayg ın Yıldırım Ebru Aypar Bur ça Aydın Canan Aky üz Hayrettin Hakan Aykan İlker Ertuğrul Tevfik Karag öz Dursun Alehan Source Type: research
Management of primary cardiac leiomyosarcoma
CONCLUSION: The nonspecific symptoms presented in the reported case demonstrate that the cardiac tumour can mimic other cardiac disorders, such as coronary artery disease or pericarditis, rarely representing the first manifestation of a previously unknown malignancy.PMID:37396103 | PMC:PMC10310325 | DOI:10.3332/ecancer.2023.1562 (Source: Ecancermedicalscience)
Source: Ecancermedicalscience - July 3, 2023 Category: Cancer & Oncology Authors: Lucrecia Aline Cabral Formigosa Luciana Ferreira Dos Santos Jaqueline Dantas Neres Martins Bianca Silva de Brito Hemilly Vasconcelos de Miranda Silva Ricardo Luiz Saldanha da Silva Josinete da Concei ção Barros do Carmo Samara Machado Castilho Source Type: research
Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment
CONCLUSIONS: According to our results, everolimus accelerates tumor mass reduction, but not amount of mass regression in the long term. Everolimus may be considered for treatment of rhabdomyomas which cause hemodynamic compromise or life-threatening arrhythmias before surgical intervention.PMID:37395967 | DOI:10.24953/turkjped.2022.922 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - July 3, 2023 Category: Pediatrics Authors: Sayg ın Yıldırım Ebru Aypar Bur ça Aydın Canan Aky üz Hayrettin Hakan Aykan İlker Ertuğrul Tevfik Karag öz Dursun Alehan Source Type: research
Management of primary cardiac leiomyosarcoma
CONCLUSION: The nonspecific symptoms presented in the reported case demonstrate that the cardiac tumour can mimic other cardiac disorders, such as coronary artery disease or pericarditis, rarely representing the first manifestation of a previously unknown malignancy.PMID:37396103 | PMC:PMC10310325 | DOI:10.3332/ecancer.2023.1562 (Source: Ecancermedicalscience)
Source: Ecancermedicalscience - July 3, 2023 Category: Cancer & Oncology Authors: Lucrecia Aline Cabral Formigosa Luciana Ferreira Dos Santos Jaqueline Dantas Neres Martins Bianca Silva de Brito Hemilly Vasconcelos de Miranda Silva Ricardo Luiz Saldanha da Silva Josinete da Concei ção Barros do Carmo Samara Machado Castilho Source Type: research
Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment
CONCLUSIONS: According to our results, everolimus accelerates tumor mass reduction, but not amount of mass regression in the long term. Everolimus may be considered for treatment of rhabdomyomas which cause hemodynamic compromise or life-threatening arrhythmias before surgical intervention.PMID:37395967 | DOI:10.24953/turkjped.2022.922 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - July 3, 2023 Category: Pediatrics Authors: Sayg ın Yıldırım Ebru Aypar Bur ça Aydın Canan Aky üz Hayrettin Hakan Aykan İlker Ertuğrul Tevfik Karag öz Dursun Alehan Source Type: research
Management of primary cardiac leiomyosarcoma
CONCLUSION: The nonspecific symptoms presented in the reported case demonstrate that the cardiac tumour can mimic other cardiac disorders, such as coronary artery disease or pericarditis, rarely representing the first manifestation of a previously unknown malignancy.PMID:37396103 | PMC:PMC10310325 | DOI:10.3332/ecancer.2023.1562 (Source: Ecancermedicalscience)
Source: Ecancermedicalscience - July 3, 2023 Category: Cancer & Oncology Authors: Lucrecia Aline Cabral Formigosa Luciana Ferreira Dos Santos Jaqueline Dantas Neres Martins Bianca Silva de Brito Hemilly Vasconcelos de Miranda Silva Ricardo Luiz Saldanha da Silva Josinete da Concei ção Barros do Carmo Samara Machado Castilho Source Type: research
Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment
CONCLUSIONS: According to our results, everolimus accelerates tumor mass reduction, but not amount of mass regression in the long term. Everolimus may be considered for treatment of rhabdomyomas which cause hemodynamic compromise or life-threatening arrhythmias before surgical intervention.PMID:37395967 | DOI:10.24953/turkjped.2022.922 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - July 3, 2023 Category: Pediatrics Authors: Sayg ın Yıldırım Ebru Aypar Bur ça Aydın Canan Aky üz Hayrettin Hakan Aykan İlker Ertuğrul Tevfik Karag öz Dursun Alehan Source Type: research
Management of primary cardiac leiomyosarcoma
CONCLUSION: The nonspecific symptoms presented in the reported case demonstrate that the cardiac tumour can mimic other cardiac disorders, such as coronary artery disease or pericarditis, rarely representing the first manifestation of a previously unknown malignancy.PMID:37396103 | PMC:PMC10310325 | DOI:10.3332/ecancer.2023.1562 (Source: Ecancermedicalscience)
Source: Ecancermedicalscience - July 3, 2023 Category: Cancer & Oncology Authors: Lucrecia Aline Cabral Formigosa Luciana Ferreira Dos Santos Jaqueline Dantas Neres Martins Bianca Silva de Brito Hemilly Vasconcelos de Miranda Silva Ricardo Luiz Saldanha da Silva Josinete da Concei ção Barros do Carmo Samara Machado Castilho Source Type: research
Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment
CONCLUSIONS: According to our results, everolimus accelerates tumor mass reduction, but not amount of mass regression in the long term. Everolimus may be considered for treatment of rhabdomyomas which cause hemodynamic compromise or life-threatening arrhythmias before surgical intervention.PMID:37395967 | DOI:10.24953/turkjped.2022.922 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - July 3, 2023 Category: Pediatrics Authors: Sayg ın Yıldırım Ebru Aypar Bur ça Aydın Canan Aky üz Hayrettin Hakan Aykan İlker Ertuğrul Tevfik Karag öz Dursun Alehan Source Type: research
